title: Comparison of gray matter and metabolic reduction in mild Alzheimer's disease using FDG-PET and voxel-based morphometric MR studies.
abstract: OBJECTIVE
  The aim of this study was to investigate regional differences between morphologic and functional changes in the same patients with mild Alzheimer's disease (AD) using statistical parametric mapping (SPM) and voxel-based morphometry (VBM).
  
  
  METHODS
  Thirty patients with very mild AD (mean age 66.8 years, mean MMSE score 24.0) and 30 age- and sex-matched normal volunteers underwent both( 18)F-fluorodeoxyglucose (FDG) positron emission tomography (PET) and three-dimensional spoiled gradient echo (SPGR) magnetic resonance imaging (MRI). Statistical parametric mapping was used to conduct VBM analysis of the morphological data, which were compared voxel by voxel with the results of a similar analysis of the glucose metabolic data.
  
  
  RESULTS
  In AD patients, VBM data indicated a significant gray matter volume density decrease in bilateral amygdala/hippocampus complex (p < 0.05, corrected), while FDG-PET analysis showed significant glucose metabolic reductions in the posterior cingulate gyri and the right parietal lobule, compared with those in the normal control group.
  
  
  CONCLUSIONS
  In very mild AD, morphological change occurs in the medial temporal lobes, while in contrast, metabolic changes occur in the posterior cingulate gyri and parietal lobule.
authors.affiliation: Department of Radiology and Nuclear Medicine, Hyogo Brain and Heart Center, 520 Saisho-Ko, Himeji, Hyogo, 670-0981, Japan. kishii@hbhc.jp
authors.forename: Kazunari
authors.initials: K
authors.lastname: Ishii
authors.forename: Hiroki
authors.initials: H
authors.lastname: Sasaki
authors.forename: Atsushi K
authors.initials: AK
authors.lastname: Kono
authors.forename: Naokazu
authors.initials: N
authors.lastname: Miyamoto
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Fukuda
authors.forename: Etsuro
authors.initials: E
authors.lastname: Mori
mesh_terms: D000465:Algorithms; D000544:Alzheimer Disease / Q000000981:diagnostic imaging / Q000378:metabolism* / Q000473:pathology*; D001921:Brain / Q000000981:diagnostic imaging / Q000378:metabolism* / Q000473:pathology*; D001931:Brain Mapping / Q000379:methods; D005260:Female; D019788:Fluorodeoxyglucose F18 / Q000493:pharmacokinetics*; D006801:Humans; D007089:Image Enhancement / Q000379:methods; D007090:Image Interpretation, Computer-Assisted / Q000379:methods; D021621:Imaging, Three-Dimensional / Q000379:methods; D008279:Magnetic Resonance Imaging / Q000379:methods*; D008297:Male; D009474:Neurons / Q000000981:diagnostic imaging / Q000378:metabolism / Q000473:pathology; D049268:Positron-Emission Tomography / Q000379:methods*; D019275:Radiopharmaceuticals; D012720:Severity of Illness Index; D012815:Signal Processing, Computer-Assisted
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18